Volume 53, Issue 2, February 2023

Expression profiles of promoters in 26 lung adenocarcinoma cell lines were determined using the transcriptional start site-sequencing data and an index ‘canonical promoter usage’ to quantify the diversity of alternative promoter usage is proposed.

The frequency of CDK4/6 inhibitor-induced ILD in clinical settings was higher than that reported in clinical trials. We did not identify any risk factors for the development of ILD in this study.

No previous studies have attempted to analyse the conditional survival for early onset colorectal cancer patients. We successfully developed nomograms to predict conditional survival with considerable prognostic accuracy for these patients.

Consolidation chemotherapy after postoperative CCRT was effective in improving survival for high-risk early-stage cervical cancer patients with specific conditions.

Dose modifications of liposomal irinotecan to minimize the adverse events during nal-IRI combination chemotherapy are critical. Gastrointestinal toxicities tend to have a prolonged time to resolution, and require careful management.

Perioperative chemotherapy improved disease-specific overall survival of a limited subset of patients with malignant peripheral nerve sheath tumors.

This is the first study to report the results of a nationwide survey in Japan analyzing ductal carcinoma of the prostate treated with radiotherapy.

Patient-perceived quality of life could be a predictive factor for the durable efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer treated with second- or later-line nivolumab.

Assessing tumour components using machine learning algorithms might be useful to stratify the post-operative prognosis of surgically resected stage IA adenocarcinomas.

A randomized phase III trial was started to confirm the superiority of the addition of preoperative chemotherapy to D2 gastrectomy with postoperative chemotherapy for patients with clinical T3–4N1–3 M0 gastric cancer.

This multi-institutional, single-arm, phase II trial is aimed at confirming the safety of ultra-HF-WBI after BCS for breast cancer in Japanese women.

The European and American uterine cervical cancer guidelines recommend delivering > 85 Gy to the CTVHR D90, the Japanese guidelines do not recommend delivering such a high dose. Subsequently, while late toxicities in the Japanese schedule are milder than those in the Western schedule, local control is also lower. In this article, we hope to raise a discussion in our community about modifying our guidelines to recommend a higher dose, at least for patients with poor response.